A Two-part, Crossover Study to Investigate the Effects of Morning Versus Evening Dosing and Food Interaction on the Pharmacodynamics and Pharmacokinetics of Single and Multiple Doses of ONO-5334 in Healthy Post Menopausal Women.
Phase of Trial: Phase I/II
Latest Information Update: 01 Jan 2016
At a glance
- Drugs ONO 5334 (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Ono Pharmaceutical
- 16 Oct 2012 Results comparing effects of morning versus evening administration on bone turnover markers presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
- 24 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
- 28 Jun 2011 Planned end date (1 Nov 2011) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History